Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Finasteride,Latanoprost,Minoxidil
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Akums Drugs & Pharmaceuticals Ltd
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Akums Drugs inks licensing pact with Canadian firm Triple Hair Inc
Details : Akums gains rights for patented topical formulation, Therapy-07, for the Indian market which combines three medicaments (finasteride,latanoprost,minoxidil) to combat alopecia.
Brand Name : Therapy-07
Molecule Type : Small molecule
Upfront Cash : Undisclosed
October 16, 2024
Lead Product(s) : Finasteride,Latanoprost,Minoxidil
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Akums Drugs & Pharmaceuticals Ltd
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Latanoprost
Therapeutic Area : Ophthalmology
Study Phase : Phase I
Sponsor : Medical Research Future Fund
Deal Size : $1.5 million
Deal Type : Funding
PolyActiva Wins $1.5M Grant for Ocular Implant in Glaucoma Treatment
Details : The company will use the grant funding to advance the PA5346 (latanoprost) second-generation -releasing ocular implant, which is being evaluated for treatment of Glaucoma.
Brand Name : PA5346
Molecule Type : Small molecule
Upfront Cash : Undisclosed
May 07, 2024
Lead Product(s) : Latanoprost
Therapeutic Area : Ophthalmology
Highest Development Status : Phase I
Sponsor : Medical Research Future Fund
Deal Size : $1.5 million
Deal Type : Funding
Lead Product(s) : QLS-111,Latanoprost
Therapeutic Area : Ophthalmology
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Qlaris Bio’s Novel IOP-Lowering Product, QLS-111, is Dosed in Phase II Trials
Details : QLS‑111, a first-in-class therapeutic being developed to lower IOP by targeting episcleral venous pressure in combination wth latanoprost for open angle glaucoma and ocular hypertension.
Brand Name : QLS-111
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 02, 2024
Lead Product(s) : QLS-111,Latanoprost
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Latanoprost
Therapeutic Area : Ophthalmology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Catiolanze® is a preservative-free latanoprost 50μg/mL eye drop cationic emulsion. The active substance latanoprost, a prostaglandin F2α analogue, is a selective proteinoid FP receptor agonist which reduces the IOP by increasing the outflow of aqueous...
Brand Name : Catiolanze
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 17, 2023
Lead Product(s) : Latanoprost
Therapeutic Area : Ophthalmology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Latanoprost
Therapeutic Area : Ophthalmology
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : PA5108 Ocular Implant with Prezia™ technology are being developed to offer a safe and effective, fully biodegradable therapy, which is investigated for the treatment of mild to moderate glaucoma.
Brand Name : PA5108
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 02, 2023
Lead Product(s) : Latanoprost
Therapeutic Area : Ophthalmology
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Latanoprost
Therapeutic Area : Ophthalmology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Thea Pharma Inc. Launches IYUZEH™ (latanoprost ophthalmic solution) 0.005% in the U.S.
Details : Iyuzeh (latanoprost) is a prostaglandin F2α analogue that is believed to reduce the IOP by increasing the outflow of aqueous humor. It is being indicated for primary open-angle glaucoma (POAG) or ocular hypertension (OHT).
Brand Name : Iyuzeh
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 26, 2023
Lead Product(s) : Latanoprost
Therapeutic Area : Ophthalmology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Latanoprost
Therapeutic Area : Ophthalmology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Iyuzeh (latanoprost) is a prostaglandin F2α analogue that is believed to reduce the IOP by increasing the outflow of aqueous humor. It is being indicated for primary open-angle glaucoma (POAG) or ocular hypertension (OHT).
Brand Name : Iyuzeh
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 03, 2023
Lead Product(s) : Latanoprost
Therapeutic Area : Ophthalmology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Netarsudil,Latanoprost
Therapeutic Area : Ophthalmology
Study Phase : Approved
Sponsor : Alcon Inc
Deal Size : $930.0 million
Deal Type : Acquisition
Details : Alcon will add Rocklatan (netarsudil and latanoprost ophthalmic solution) and Rhopressa (netarsudil ophthalmic solution), as well as AR-15512, a Phase 3 candidate for dry eye disease, and a pipeline of several clinical and preclinical ophthalmic pharmace...
Brand Name : Rocklatan
Molecule Type : Small molecule
Upfront Cash : Undisclosed
December 22, 2022
Lead Product(s) : Netarsudil,Latanoprost
Therapeutic Area : Ophthalmology
Highest Development Status : Approved
Sponsor : Alcon Inc
Deal Size : $930.0 million
Deal Type : Acquisition
Lead Product(s) : Latanoprost
Therapeutic Area : Ophthalmology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : IYUZEH™ is the first and only clinically proven formulation of latanoprost available in the United States that is preservative-free. IYUZEH™ is formulated without any of the preservatives commonly used in topical ocular preparations, including benzal...
Brand Name : Iyuzeh
Molecule Type : Small molecule
Upfront Cash : Not Applicable
December 14, 2022
Lead Product(s) : Latanoprost
Therapeutic Area : Ophthalmology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Netarsudil,Latanoprost
Therapeutic Area : Ophthalmology
Study Phase : Approved
Sponsor : Alcon Inc
Deal Size : Undisclosed
Deal Type : Acquisition
Details : Through the transaction, Alcon has added the commercial products Rocklatan (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% and Rhopressa (netarsudil ophthalmic solution) 0.02%, as well as AR-15512, a Phase 3 product candidate for dry eye di...
Brand Name : Rocklatan
Molecule Type : Small molecule
Upfront Cash : Undisclosed
November 22, 2022
Lead Product(s) : Netarsudil,Latanoprost
Therapeutic Area : Ophthalmology
Highest Development Status : Approved
Sponsor : Alcon Inc
Deal Size : Undisclosed
Deal Type : Acquisition
LOOKING FOR A SUPPLIER?